drugset / Trial / NCT04427241

Efficacy and Safety of Cerebrolysin on Prolonged Disorders of Consciousness

NCT04427241

RandomizedParallel-groupQuadruple-blindTreatment

Summary

Object: To determine the effect of cerebrolysin on prolonged disorders of consciousness caused by hemorrhagic stroke. Participants: patients with prolonged disorders of consciousness due to severe traumatic brain injury Intervention: 30 ml cerebrolysin + 70 ml normal saline, days 4-17, once/day, intravenously or 100 ml normal saline, days 4-17, once/day, IV Comparison: cerebrolysin group versus control group Outcome: Coma Recovery Scale-revised, FDG-PET signal

Timeline

Start
2023-06-01
Primary completion
2026-09-30
Completion
2026-12-31

Drugs

EvaluationDrugModalityDoseRoute
Subject Cerebrolysin Peptide 30 ml Intravenous

Indications